检索结果-南通市图书馆

Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

引用

World Journal of Gastroenterology 2024年第7期30卷 685-704页

作者： Marcello Dallio Mario Romeo Paolo Vaia Salvatore Auletta Simone Mammone Marina Cipullo luigi sapio Angela Ragone Marco Niosi Silvio Naviglio Alessandro Federico Department of Precision Medicine Hepatogastroenterology DivisionUniversity of Campania Luigi VanvitelliNaples 80138Italy Department of Precision Medicine Clinical Biochemistry DivisionUniversity of Campania Luigi VanvitelliNaples 80138Italy

BACKGROUND For compensated advanced chronic liver disease(cACLD)patients,the first decompensation represents a dramatically worsening prognostic event.Based on the first decompensation event(DE),the transition to decompensated advanced chronic liver disease(dACLD)can occur through two modalities referred to as acute decompensation(AD)and non-AD(NAD),respectively.Clinically Significant Portal Hypertension(CSPH)is considered the strongest predictor of decompensation in these patients.However,due to its invasiveness and costs,CSPH is almost never evaluated in clinical practice.Therefore,recognizing noninvasively predicting tools still have more appeal across healthcare systems.The red cell distribution width to platelet ratio(RPR)has been reported to be an indicator of hepatic fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD).However,its predictive role for the decompensation has never been explored.AIM In this observational study,we investigated the clinical usage of RPR in predicting DEs in MASLD-related cACLD patients.METHODS Fourty controls and 150 MASLD-cACLD patients were consecutively enrolled and followed up(FUP)semiannually for 3 years.At baseline,biochemical,clinical,and Liver Stiffness Measurement(LSM),Child-Pugh(CP),Model for End-Stage Liver Disease(MELD),aspartate aminotransferase/platelet count ratio index(APRI),Fibrosis-4(FIB-4),Albumin-Bilirubin(ALBI),ALBI-FIB-4,and RPR were collected.During FUP,DEs(timing and modaities)were recorded.CSPH was assessed at the baseline and on DE occurrence according to the available Clinical Practice Guidelines.RESULTS Of 150 MASLD-related cACLD patients,43(28.6%)progressed to dACLD at a median time of 28.9 months(29 NAD and 14 AD).Baseline RPR values were significantly higher in cACLD in comparison to controls,as well as MELD,CP,APRI,FIB-4,ALBI,ALBI-FIB-4,and LSM in dACLD-progressing compared to cACLD individuals[all P0.472 and>0.894 as the best

关键词： Liver cirrhosis Red blood cell distribution width Red blood cell distribution width to platelet ratio Translational Medicine Prognostic biomarker

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

AdipoRon and Pancreatic Ductal Adenocarcinoma:a future perspective in overcoming chemotherapyinduced resistance?

引用

Cancer Drug Resistance 2022年第3期5卷 625-636页

作者： luigi sapio Angela Ragone Annamaria Spina Alessia Salzillo Silvio Naviglio Department of Precision Medicine University of Campania“Luigi Vanvitelli”Naples 80138Italy

The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma(PDAC).Among the causative factors,the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvement in PDAC survival over the years.Even though several compounds have achieved encouraging results at preclinical stage,no new adjuvant agents have reached the bedside of PDAC patients lately.The adiponectin receptor agonist AdipoRon is emerging as a promising anticancer drug in different cancer models,particularly in PDAC.Building on the existing findings,we recently reinforced its candidacy in PDAC cells,proposing AdipoRon either as a suitable partner in gemcitabinebased treatment or as an effective drug in resistant cells.Crossing the current state-of-the-art,herein we provide a critical perspective on AdipoRon to figure out whether this receptor agonist can potentially be considered a future therapeutic choice in overcoming chemotherapy-induced resistance,expressly in PDAC.

关键词： PDAC AdipoRon gemcitabine resistance

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Inorganic phosphate in the development and treatment of cancer:A Janus Bifrons?

引用

World Journal of Clinical Oncology 2015年第6期6卷 198-201页

作者： luigi sapio Silvio Naviglio Department of Biochemistry Biophysics and General PathologyMedical SchoolSecond University of Naples

Inorganic phosphate(Pi) is an essential nutrient to living organisms. It is required as a component of the energy metabolism,kinase/phosphatase signaling and in the formation and function of lipids,carbohydrates and nucleic acids and,at systemic level,it plays a key role for normal skeletal and dentin mineralization. Pi represents an abundant dietary element and its intestinal absorption is efficient,minimally regulated and typically extends to approximately 70%. Maintenance of proper Pi homeostasis is a critical event and serum Pi level is maintained within a narrow range through an elaborate network of humoral interactions and feedback loops involving intestine,kidney,parathyroid gland and bone,and depends on the activity of a number of hormones,including parathyroid hormone,1,25-dihydroxy vitamin D,and fibroblast growth factor 23 as major regulators of Pi homeostasis. Notably,Pi intake seemingly continues to increase as a consequence of chronic high-phosphorus(P) diets deriving from the growing consumption of highly processed foods,especially restaurant meals,fast foods,and convenience foods. Several recent reports have generated significant associations between high-P intake or high-serum Pi concentration and morbidity and mortality. Many chronic diseases,including cardiovascular diseases,obesity and even cancer have been proposed to be associated with high-P intakes and high-serum Pi concentrations. On the other hand,there is also evidence that Pi can have antiproliferative effects on some cancer cell types,depending on cell status and genetic background and achieve additive cytotoxic effects when combined with doxorubicin,illustrating its potential for clinical applications and suggesting that up-regulating Pi levels at local sites for brief times,might contribute to the development of novel and cheap modalities for therapeutic intervention in some tumours. Overall,the influence of Pi on cell function and the possible relationship to cancer have to be fully understood and investigated further.

关键词： Calcium-phosphate nanoparticles Inorganic phosphate Cancer High-phosphorus diets Phosphorus intake Doxorubicin Combination therapy Naturally occurring molecule Osteosarcoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：